Total Payments
$676,192
2024 Payments
$40.72
Companies
56
Transactions
1,003
Medicare Patients
6,506
Medicare Billing
$751,228
Payment Breakdown by Category
Research$594,288 (87.9%)
Other$46,807 (6.9%)
Food & Beverage$16,245 (2.4%)
Consulting$7,610 (1.1%)
Travel$5,892 (0.9%)
Education$5,349 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $594,288 | 74 | 87.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $46,807 | 27 | 6.9% |
| Food and Beverage | $16,245 | 869 | 2.4% |
| Consulting Fee | $7,610 | 3 | 1.1% |
| Travel and Lodging | $5,892 | 21 | 0.9% |
| Education | $5,349 | 9 | 0.8% |
Payments by Type
Research
$594,288
74 transactions
General
$81,904
929 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc. | $472,964 | 38 | $0 (2018) |
| Lupin Inc. | $76,378 | 21 | $0 (2018) |
| GlaxoSmithKline, LLC. | $34,296 | 217 | $0 (2023) |
| Eli Lilly and Company | $28,380 | 7 | $0 (2023) |
| Mylan Specialty L.P. | $24,182 | 63 | $0 (2023) |
| PFIZER INC. | $10,637 | 5 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $7,512 | 130 | $0 (2023) |
| Mylan Inc. | $7,154 | 8 | $0 (2021) |
| GENZYME CORPORATION | $2,989 | 23 | $0 (2023) |
| Genentech USA, Inc. | $2,086 | 21 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40.72 | 2 | ATRICURE, INC. ($26.31) |
| 2023 | $13,807 | 64 | PFIZER INC. ($10,618) |
| 2022 | $11,590 | 179 | Eli Lilly and Company ($8,394) |
| 2021 | $17,517 | 184 | Mylan Inc. ($7,154) |
| 2020 | $30,268 | 138 | Eli Lilly and Company ($14,625) |
| 2019 | $38,638 | 218 | GlaxoSmithKline, LLC. ($17,187) |
| 2018 | $171,245 | 102 | Glenmark Pharmaceuticals Inc. ($85,063) |
| 2017 | $393,086 | 116 | Glenmark Pharmaceuticals Inc. ($387,901) |
All Payment Transactions
1,003 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/23/2024 | ATRICURE, INC. | ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.41 | General |
| 10/10/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: COVID-19 | ||||||
| 09/21/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $3,718.80 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 09/06/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: COVID-19 | ||||||
| 08/30/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: COVID-19 | ||||||
| 08/25/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $14.14 | General |
| Category: HFCWO | ||||||
| 08/03/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $165.60 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 07/21/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $10.08 | General |
| Category: HFCWO | ||||||
| 07/10/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $8.58 | General |
| 06/29/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.34 | General |
| 06/20/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $15.15 | General |
| Category: HFCWO | ||||||
| 06/12/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.95 | General |
| 05/23/2023 | Body Vision Medical Inc. | LungVision (Device) | Food and Beverage | Cash or cash equivalent | $22.61 | General |
| Category: Interventional Pulmonology | ||||||
| 05/23/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.95 | General |
| 05/16/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $16.63 | General |
| Category: HFCWO | ||||||
| 05/04/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $165.60 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 05/01/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $31.21 | General |
| Category: Infections and Infectious Diseases | ||||||
| 04/26/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $6,568.20 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 04/25/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $12.79 | General |
| Category: Immunology | ||||||
| 04/14/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $16.22 | General |
| Category: HFCWO | ||||||
| 04/11/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: RESPIRATORY | ||||||
| 04/10/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: RESPIRATORY | ||||||
| 04/07/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: Respiratory | ||||||
| 03/30/2023 | Baxter Healthcare | Hillrom - Life 2000 Ventilation System (Device) | Food and Beverage | In-kind items and services | $33.83 | General |
| Category: Airway Clearance Device | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP304-201 | Glenmark Pharmaceuticals Inc. | $387,901 | 33 |
| Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Glenmark Pharmaceuticals Inc. | $85,063 | 5 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $70,378 | 19 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $15,529 | 3 |
| A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | PFIZER INC. | $10,618 | 4 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $10,072 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $6,000 | 2 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $2,044 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $734.83 | 1 |
| A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $189.08 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 465 | 1,234 | $105,385 | $49,380 |
| 2022 | 21 | 2,037 | 5,298 | $561,121 | $254,912 |
| 2021 | 20 | 1,993 | 5,819 | $534,313 | $266,849 |
| 2020 | 25 | 2,011 | 3,833 | $482,720 | $180,086 |
Total Patients
6,506
Total Services
16,184
Medicare Billing
$751,228
Procedure Codes
81
All Medicare Procedures & Services
81 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 208 | 323 | $46,835 | $26,551 | 56.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 77 | 110 | $18,150 | $11,080 | 61.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 21 | 21 | $4,515 | $3,070 | 68.0% |
| 31645 | Aspiration of initial secretion of lung airway using an endoscope | Office | 2023 | 20 | 21 | $11,550 | $2,036 | 17.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 29 | $6,525 | $1,781 | 27.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $4,400 | $1,598 | 36.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $3,630 | $1,477 | 40.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 11 | $1,045 | $727.11 | 69.6% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 36 | 636 | $6,360 | $451.12 | 7.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 36 | 43 | $1,075 | $367.85 | 34.2% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 13 | 13 | $1,300 | $242.60 | 18.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 569 | 1,246 | $180,670 | $111,715 | 61.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 278 | 470 | $78,645 | $56,885 | 72.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 117 | 117 | $25,415 | $17,973 | 70.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 45 | 109 | $36,085 | $8,743 | 24.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 80 | 158 | $35,565 | $8,572 | 24.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 76 | 80 | $22,536 | $7,744 | 34.4% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 79 | 142 | $8,993 | $6,389 | 71.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 68 | 75 | $7,125 | $4,769 | 66.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 25 | 28 | $25,727 | $4,673 | 18.2% |
| 31645 | Aspiration of initial secretion of lung airway using an endoscope | Facility | 2022 | 35 | 41 | $25,663 | $4,299 | 16.8% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 175 | 179 | $17,900 | $3,356 | 18.7% |
| 31645 | Aspiration of initial secretion of lung airway using an endoscope | Office | 2022 | 30 | 31 | $17,050 | $2,933 | 17.2% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Office | 2022 | 31 | 38 | $19,950 | $2,911 | 14.6% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2022 | 28 | 30 | $15,962 | $2,884 | 18.1% |
About Dr. Gregory Feldman, MD
Dr. Gregory Feldman, MD is a Critical Care Medicine healthcare provider based in Columbia, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710942305.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Feldman, MD has received a total of $676,192 in payments from pharmaceutical and medical device companies, with $40.72 received in 2024. These payments were reported across 1,003 transactions from 56 companies. The most common payment nature is "" ($594,288).
As a Medicare-enrolled provider, Feldman has provided services to 6,506 Medicare beneficiaries, totaling 16,184 services with total Medicare billing of $751,228. Data is available for 4 years (2020–2023), covering 81 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Critical Care Medicine, Pulmonary Disease
- Location Columbia, SC
- Active Since 04/18/2006
- Last Updated 03/06/2024
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1710942305
Products in Payments
- TIOTROPIUM (Drug) $70,378
- Yupelri (Drug) $31,172
- TRELEGY ELLIPTA (Drug) $23,311
- NURTEC ODT (Drug) $10,618
- ANORO (Drug) $6,493
- ADVAIR (Drug) $6,000
- DUPIXENT (Biological) $3,199
- Xolair (Biological) $1,977
- SMARTVEST (Device) $1,026
- NUCALA (Biological) $774.27
- SYMBICORT (Drug) $686.89
- STIOLTO RESPIMAT (Drug) $603.55
- BREZTRI (Drug) $492.41
- (8874) inCourage (Device) $399.91
- XOLAIR (Biological) $371.22
- BEVESPI AEROSPHERE (Drug) $355.31
- LONHALA MAGNAIR (Drug) $345.50
- TEZSPIRE (Biological) $345.26
- REMODULIN (Drug) $330.00
- OFEV (Drug) $324.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Columbia
Aaron Miller, M.d, M.D
Critical Care Medicine — Payments: $63,074
Critical Care Medicine $63,074
Jon Freels, M.d, M.D
Critical Care Medicine — Payments: $28,648
Critical Care Medicine $28,648
Stevan Whitt, M.d, M.D
Critical Care Medicine — Payments: $15,437
Critical Care Medicine $15,437
Dr. Vrinda Trivedi, Mbbs, MBBS
Critical Care Medicine — Payments: $8,056
Critical Care Medicine $8,056
Dr. Abhinav Gupta, M.d, M.D
Critical Care Medicine — Payments: $6,851
Critical Care Medicine $6,851
Syed Gilani, Md, MD
Critical Care Medicine — Payments: $6,816
Critical Care Medicine $6,816